Table 3.
Individual patient level demographics and outcomes
| ID | Age (yr) | Sex | Race | Diagnosis | ECOG PS | Child-Pugh | 90Y dose (Gy) | 90Y volume (mL) | 90Y-SBRT interval (mo) | SBRT dose (Gy) | SBRT volume (mL) | Response | PV patency | OS (mo) | SBRT related toxicities |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 67 | F | White | HCC | 0 | A | 83.3 | 675 | 1 | 50 | 64.2 | PR | Yes | 13+ | Grade 1 fatigue |
| 2 | 65 | M | Asian | HCC | 0 | B | 110.6 | 897 | 1 | 30 | 91.8 | SD | No | 12+ | None |
| 3 | 47 | M | White | HCC | 1 | A | 124.7 | 1,011 | 2 | 30 | 150.9 | SD | No | 5+ | Grade 1 nausea |
| 4 | 81 | F | White | HCC | 1 | A | 99.9 | 810 | 1 | 40 | 266.1 | PD | No | 2 | Grade 1 elevated LFTs |
| 5 | 57 | M | Asian | HCC | 1 | A | 131.7 | 1,068 | 4 | 50 | 192.4 | PR | Yes | 8 | Grade 1 fatigue |
| 6 | 57 | F | Hispanic | Liver metastasis | 1 | A | 103.6 | 840 | 3 | 27.5 | 61.1 | CR | Yes | 14 | None |
| 7 | 71 | M | White | HCC | 0 | B | 91.4 | 741 | 2 | 35 | 90.9 | PD | No | 4 | Grade 1 nausea |
| 8 | 61 | F | Asian | CCC | 0 | A | 105.1 | 852 | 2 | 27.5 | 23.2 | SD | Yes | 45+ | None |
| 9 | 67 | M | White | HCC | 2 | B | 121.4 | 984 | 1 | 30 | 60.4 | SD | No | 7 | None |
| 10 | 56 | F | Hispanic | CCC | 0 | A | 99.5 | 807 | 5 | 40 | 386.6 | PR | Yes | 10+ | Grade 1 esophagitis |
| 11 | 66 | M | Asian | HCC | 0 | A | 97.7 | 792 | 5 | 45 | 623.2 | PR | Yes | 29+ | Grade 1 elevated LFTs |
| 12 | 83 | M | Asian | HCC | 0 | A | 107.3 | 870 | 5 | 27.5 | 14.7 | PR | Yes | 33 | None |
ECOG PS, Eastern Cooperative Oncology Group performance status; SBRT, stereotactic body radiation therapy; PV, portal vein; OS, overall survival; HCC, hepatocellular carcinoma; CCC, cholangiocarcinoma; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; +, still alive; LFT, liver function test.